Articles tagged with Cancer Medication
Cancers resistant to radiotherapy may be rendered susceptible through immunotherapy treatment, according to a new study. The research found that profiling the immune landscape of cancers before therapy can identify patients who are likely to respond well or poorly to radiotherapy.
Researchers at Lund University have developed a new method for generating antibodies using CRISPR-Cas9, which enables the identification of novel target molecules and could lead to more effective treatments for cancer and autoimmune diseases.
A new study found that cancer survivors who walked at a slow pace had a significantly increased risk of death from any cause, with the association holding for nine cancer types. The researchers call for more research into targeted interventions to improve walking ability and increase survival among cancer patients.
Scientists have isolated a peptide, EnnA, from a fungus in Morocco that directly inhibits HSP90, a powerful cell protector hijacked by cancer. Early evidence shows EnnA induces immune cells to attack cancer cells, promoting immunogenic cell death and potentially offering a new treatment for triple negative breast cancer.
Researchers at Baylor College of Medicine identified proteomic signatures associated with aggressive cancer types, including altered cellular pathways and novel therapeutic targets. The study provided proof-of-concept that proteomics analysis is a valuable strategy to identify potential therapeutic targets.
Researchers have created a boron-containing chemical group that is 10,000 times more stable than its predecessors. This new group, called benzoxaboralone, can be added to compounds to provide desirable attributes such as improved protein-binding strength.
Researchers have discovered that malignant rhabdoid tumour (MRT) arises from developmental cells in the neural crest whose maturation is blocked by a genetic defect. The study identified two drugs that could be used to overcome this block and resume normal development, bringing hope for new treatments.
Researchers at Hong Kong Baptist University develop a peptide-linked drug targeting two viral proteins produced by Epstein-Barr virus, reducing cancer cell damage and increasing drug uptake rates. The novel drug has shown efficacy in animal models and is being further developed for clinical trials.
Researchers develop targeted immunotherapy approach that specifically kills cancer cells by targeting mutant protein fragments presented on the cell surface. The therapy uses bispecific antibodies to recognize and destroy cancer cells, bypassing conventional antibody limitations.
Scientists have identified a region within the GLI1 gene responsible for regulating its expression, providing a potential target for cancer treatment. Removing this region eliminates GLI1 activity, halting excessive cell division characteristic of cancer.
Researchers identified various molecular pathways and predictive biomarkers of drug resistance in diffuse large B-cell lymphoma. Tailored therapies can improve prognosis for patients with refractory disease, particularly those with specific clinical features.
Researchers discovered artificial microswimmers slow down and accumulate in low-fuel regions where their speed is minimized. This finding suggests a new strategy to improve targeted cancer therapy by delivering chemotherapy drugs to the most problematic cells.
Researchers developed polymeric nano-micelles that target specific levels of c-Myc expression, a key factor in cancer cell proliferation. The study showed varying efficacy depending on tumor c-Myc expression levels, with higher expression associated with better antitumor activity.
A study by the Mays Cancer Center at UT Health San Antonio found that bladder cancer is more advanced and deadly in South Texas residents than in many parts of the country. The disease disproportionately affects Latinos and women, with worse survival rates regardless of geographic location.
The ESMO Targeted Anticancer Therapies Congress 2021 presented new data on drug discovery and development for a range of targets, including precision medicine. World-renowned experts discussed breakthroughs in the microbiome and oncolytic viruses, highlighting their potential as tools and targets.
A new study by Yale Cancer Center found sex hormones and insulin growth factors are associated with recurrence risk of endometrial cancer. The findings suggest a possible new approach in the prevention and treatment of endometrial cancer recurrence, which is currently being evaluated in a multi-center trial.
A recent study found that MYCN overexpression leads to increased iron levels, which induce ferroptosis, a type of cell death. This vulnerability can be exploited by drugs blocking ROS elimination, making cancer cells susceptible to treatment. The researchers plan to test FDA-approved rheumatoid arthritis drugs in preclinical models.
NYUAD researchers have developed a new technology that enables the creation of high throughput arrays of miniaturized 3D tumor models, which can be safely cryopreserved and stored for on-demand drug testing use. This technology has the potential to revolutionize personalized medicine by predicting the outcomes of drug efficacy.
The study demonstrates MEK inhibitors as a promising targeted therapy for basal subtype bladder cancer, highlighting the importance of 3D cell culture drug screening. Established genomic and transcriptomic data are correlated with drug response to identify novel groups of tumors vulnerable to specific drugs.
Scientists at the University of Cambridge have identified a potential new treatment to protect immunosuppressed transplant patients from HCMV reactivation, which can cause serious illness and death. The 'shock and kill' treatment strategy uses epigenetic inhibitors to expose and destroy dormant HCMV infections.
Researchers have found that short strands of cell-free DNA in urine can indicate a difference between healthy individuals and those with cancer. The DNA fragments are protected from degradation and can provide meaningful information about disease complexity like cancer.
Researchers have used a new technique to track the reaction of Osmium in single lung cancer cells, providing crucial insights into potential cellular targets for new cancer treatments. The findings could lead to the development of sustainable and effective treatments using Osmium as a catalyst.
Researchers at Medical University of Vienna have found a previously unknown molecular connection between an inflammatory signalling molecule and one of the main oncogenes, c-Myc. This interaction causes slower degradation of c-Myc, leading to higher cell division rates and resistance to chemotherapeutics.
A study by the University of Zurich found that 63% of drugs with rebates granted in Switzerland have low clinical benefits, while 49% have no significant benefit. The research highlights the need for transparent cooperation between European countries to improve drug pricing and patient access.
The article discusses the relationship between DNA repair pathways and cancer cells, highlighting five critical pathways and their impact on cancer evolution. The review suggests potential clinical interventions to address pathway damage, offering new insights into cancer treatment.
Researchers at McMaster University have discovered a dopamine receptor pathway that becomes abnormally activated in acute myeloid leukemia (AML) cancer stem cells. This led to the clinical investigation of thioridazine as a new therapy for adult AML patients, revealing encouraging results.
Ruth Plummer, a renowned Clinical Professor and Honorary Consultant Medical Oncologist, has been awarded the TAT 2021 Honorary Award. Her tireless work in clinical trials has led to the development of numerous standard treatments for proven patient benefit.
Researchers identified two unique subtypes of NPM1-mutated Acute Myeloid Leukemia (AML), one potentially treatable with existing drugs, and the other requiring new therapeutic approaches. This discovery may lead to improved treatment outcomes and personalized medicine for patients.
Researchers found that disrupting the effect of the tumor microenvironment on immune cells in mice allowed for shrinking tumors, prolonging survival and increasing sensitivity to immunotherapy. Silencing a key protein MCT1 caused tumor growth to slow down and killer T cells could attack cancer.
A SWOG Cancer Research Network trial found cabozantinib to be the most effective treatment for patients with metastatic papillary kidney cancer, with a median progression-free survival of 9.2 months compared to 5.6 months with sunitinib. Additionally, 23% of patients experienced significant tumor reduction with cabozantinib.
The combination of lenvatinib and pembrolizumab significantly improved overall survival, progression-free survival, and response rates compared to sunitinib in untreated patients with metastatic kidney cancer. The study results demonstrate the importance of immune checkpoint inhibitors in first-line treatment.
Researchers have identified a potential revolutionary drug combination that is 'spectacularly effective' in eradicating DIPG cancer cells. The treatment, a combination of difluoromethylornithine (DFMO) and AMXT 1501, was found to be highly effective in animal studies and pre-clinical testing.
A new class of antibiotic-drug conjugate (ADC) drugs has been found to significantly increase the survival rate of patients with bladder cancer. The study, led by Queen Mary University of London, showed that the drug reduced the risk of death by 30% compared to chemotherapy, with a median survival time of approximately 13 months.
A study published in Nature Communications found that green tea compound epigallocatechin gallate (EGCG) preserves the tumor-suppressing protein p53 from degradation. This interaction increases p53 levels, which can aid in DNA repair and destroy cancerous cells.
Researchers discovered that immunomodulatory drugs like lenalidomide and pomalidomide starve cancer cells by destabilizing essential surface proteins, ultimately inhibiting tumor growth. This finding opens up new possibilities for targeted therapies in multiple myeloma.
Researchers develop new strategy to stop glioblastoma cell growth by inhibiting PRMT5 enzyme, leading to cellular senescence and tumor suppression. The study provides hope for treating this deadly brain cancer with a new class of drugs.
A new study reveals that nearly every cell has its own clock, which controls various aspects of homeostasis and organ function. Disruption of the clock can lead to diseases such as diabetes, cancer, and cardiovascular disease, highlighting the importance of tuning our internal time with the environment.
Researchers developed a metal organic framework (ZIF) that improves the delivery and sustained release of cancer immunotherapy drugs like nivolumab, targeting leukemia cells with minimal toxicity. Coating ZIF with a cancer cell membrane enhances accurate delivery to solid tumors.
A recent study published in PLOS Pathogens identified a key pathway that Ebola uses to gain entry into human cells. The researchers found that a specific FDA-approved drug can prevent the virus from using this pathway, potentially leading to new treatment options for Ebola patients.
A new study reveals that the behavior of p53, a key tumor-suppressor protein, over time determines whether tissues can survive radiation exposure. In vulnerable tissues, p53 levels remain high, leading to cell death, while in more radioresistant tissues, p53 levels oscillate, allowing cells to survive.
A new drug, ProAgio, has been shown to be effective in treating pancreatic cancer and prolonging survival in mice. It works by inducing apoptosis in cancer-associated fibroblasts, reducing the dense stroma that protects tumors from immune systems and conventional drugs.
Researchers found bevacizumab significantly improved blood oxygen levels, body temperature, and inflammatory markers in severe COVID-19 patients. The treatment also reduced the need for oxygen support and shortened hospital stays.
Researchers found fecal transplant increased immune cell activation and decreased immunosuppression in responders, suggesting a link between gut microbiome changes and treatment effectiveness. The study's results raise hope for microbiome-based therapies of cancers.
A new study suggests that fecal microbiota transplants can help patients with advanced melanoma respond to immunotherapy drugs. After receiving a transplant, six out of 15 patients showed improved cancer stability or tumor reduction.
Researchers studied how modern immunotherapeutic anti-cancer drugs interact with the immune system, finding that tiny molecular motions are key to their effectiveness. The study, published in Cancers, reveals how these drugs bind to specific receptors on killer cells without activating them.
A University of Colorado Boulder study suggests that existing PARP inhibitors for hereditary breast and ovarian cancers may not work as intended. The research reveals a previously unknown interaction between the PARP protein and HPF1, which could lead to more effective treatments by targeting this co-protein.
Researchers at the University of South Australia have developed a new 3D printed oesophageal stent that contains an active pharmaceutical ingredient, allowing for sustained anti-cancer medication delivery directly to the cancer site. This technology has the potential to revolutionize treatment for patients with oesophageal cancer.
Researchers at Terasaki Institute for Biomedical Innovation have developed a breast cancer-on-a-chip system to test immunotherapy drugs. The chip enables high-volume testing of immunotherapeutic drugs against tumor cells, allowing for the rapid screening of potential treatments.
Dr. Mikhail V. Blagosklonny reviews drugs that extend lifespan and healthspan in mammals, including rapamycin and metformin. He concludes that using these drugs could be the only way to live longer, given current understanding of aging.
Houston Methodist researchers created a mathematical model to predict how specific cancers will respond to immunotherapy treatments, enhancing chances for successful treatments. The model uses laws of physics and chemistry to describe complex biological systems involved in immunotherapy treatment and the associated immune response.
A study by University of Iowa researchers found that administering a neuroprotective compound during pregnancy can prevent long-term neurodevelopmental problems associated with prenatal stress. The research showed that the compound, P7C3-A20, protected the developing brain from damage caused by chronic prenatal stress.
Researchers at Tokyo University of Science explore the structure of porphyrin derivatives to selectively target cancer cells and improve drug delivery. They found that meso-derivatives accumulate in cells at 3-fold higher amounts than β-derivatives, and that smaller functional groups allow better aggregation.
Researchers have designed a new way to deliver drugs to pancreatic tumors using nanoparticles, which effectively targets the disease while minimizing toxic side effects. The technology has shown promising results in suppressing cancer cell growth and increasing sensitivity to chemotherapy drugs.
The Lung-MAP trial has amassed a scientifically valuable cache of data and biospecimens from 3,021 patients. Research presentations at the World Conference on Lung Cancer highlighted associations between tumor mutational burden and clinical outcomes to immunotherapy.
Researchers identified genetic and gene expression changes that can predict tumor response to immunotherapy, with higher mutation rates linked to better outcomes. The study's findings aim to improve treatment decisions and identify alternative options for patients who don't respond to current treatments.
Researchers developed a technique combining dPCR and HSAFM to diagnose DNA rearrangement mutations with high accuracy and low cost. The technology accurately identified FLT3 gene mutations in patients with acute myeloid leukemia, offering a potential powerful tool for cancer diagnosis.
Researchers develop innovative approach to treating bone tumors by starving cancer cells of their energy source, potentially replacing toxic chemo with a less harmful treatment. The two-drug combination showed promise in mice studies, outperforming a commonly used chemotherapy drug without severe side effects.
A study published in JAMA found that the risk of stroke following a transient ischemic attack (TIA) has decreased over time, from 23.9% to 7.6%. Despite this improvement, patients with TIAs still face a significant risk of subsequent stroke, emphasizing the need for ongoing monitoring and management of cardiovascular risk factors.
Northern Arizona University will test Allarity drug stenoparib against the highly infectious Coronavirus Variant B117, a variant found in the UK and US that spreads more easily than other variants. The testing aims to validate the antiviral activity of stenoparib against this variant.
Researchers developed a BCL strategy to generate highly potent tumor-targeted drugs from non-toxic compounds within the tumor, avoiding decomposition and side effects. The targeting drug Ru-rhein exhibits high anti-cancer activity against lung cancer cells while being non-toxic to normal cells.